Choroidal Neovascularization (CNV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Choroidal Neovascularization (CNV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017

Summary

GlobalData, the industry analysis specialist, has released its new report, “Choroidal Neovascularization (CNV) Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global Choroidal Neovascularization Therapeutics market. The report identifies the key trends shaping and driving the global Choroidal Neovascularization Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Choroidal Neovascularization Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Choroidal Neovascularization Therapeutics market. Its scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Choroidal Neovascularization Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Choroidal Neovascularization Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Choroidal Neovascularization Therapeutics therapeutics market.
- Analysis of key recent licensing and partnership agreements in Choroidal Neovascularization Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Choroidal Neovascularization Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Choroidal Neovascularization Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Choroidal Neovascularization Therapeutics market landscape? – Identify, understand and capitalize.

1 Table of contents
1 Table of contents
1.1 List of Tables
1.2 List of Figures
2 Choroidal Neovascularization Therapeutics - Introduction
2.1 Disease Overview
2.2 Etiology and Pathophysiology
2.3 Epidemiology
2.4 Signs and Symptoms
2.5 Diagnosis
2.5.1 History
2.5.2 Amsler Grid
2.5.3 Fluorescein Angiography
2.5.4 Optical Coherence Tomography (OCT)
2.5.5 Opthalmoscopy or Fundoscopy
2.5.6 Visual Acuity Testing
2.6 Treatment and Management Pattern
2.7 Pipeline Report Guidance
3 Choroidal NeovascularizationTherapeutics - Market Characterization
3.1 Overview
3.2 Choroidal Neovascularization Therapeutics Market Size
3.3 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Global
3.4 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Global
3.5 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – The US
3.6 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – The US
3.7 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – France
3.8 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – France
3.9 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Germany
3.10 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Germany
3.11 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Italy
3.12 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Italy
3.13 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Spain
3.14 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Spain
3.15 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – The UK
3.16 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – The UK
3.17 Choroidal Neovascularization Therapeutics Market Size (2005-2010) – Japan
3.18 Choroidal Neovascularization Therapeutics Market Forecast (2010-2017) – Japan
3.19 Drivers and Barriers for the Choroidal Neovascularization Therapeutics Market
3.19.1 Drivers for the Choroidal Neovascularization Therapeutics Market
3.19.2 Barriers for the Choroidal Neovascularization Therapeutics Market
3.20 Opportunity and Unmet Need Analysis
3.21 Key Takeaway
4 Choroidal Neovascularization Therapeutics - Competitive Assessment
4.1 Overview
4.2 Strategic Competitor Assessment
4.3 Product Profile for the Major Marketed Products in the CNV Therapeutics market
4.3.1 Lucentis (ranibizumab)
4.3.2 Visudyne (verteporfin)
4.3.3 Macugen (pegatanib sodium)
4.3.4 Avastin (bevacizumab)
4.4 Key Takeaway
5 Choroidal Neovascularization Therapeutics - Pipeline Assessment
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Choroidal Neovascularization Therapeutics Pipeline – Pipeline by Phases of Development
5.3.1 Choroidal Neovascularization Therapeutics – Phase III Pipeline
5.3.2 Choroidal Neovascularization Therapeutics – Phase II Pipeline
5.3.3 Choroidal Neovascularization Therapeutics – Phase I Pipeline
5.3.4 Choroidal Neovascularization Market – Discovery and Pre-clinical Pipeline
5.4 Technology Trends Analytic Framework
5.5 Choroidal Neovascularization Therapeutics Market –Pipeline by Mechanism of Action
5.6 Choroidal Neovascularization Therapeutics – Promising Drugs Under Clinical Development
5.7 Molecule Profile for Promising Drugs under Clinical Development
5.7.1 Eylea (VEGF Trap-Eye)
5.8 Key Takeaway
6 Choroidal Neovascularization Therapeutics - Clinical Trials Mapping
6.1 Clinical Trials by Region/Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Trial Status
6.4 Prominent Sponsors
6.5 Top Companies Participating in Choroidal Neovascularization Therapeutics Clinical Trials
7 Strategic Assessment
7.1 Key Events Impacting the Future Market
7.2 Future Market Competition Scenario
7.3 Choroidal Neovascularization Therapeutics - Implications for Future Market Competition
8 Choroidal Neovascularization Therapeutics - Future Players
8.1 Introduction
8.2 Company Profiles
8.2.1 Genentech/F. Hoffmann-La Roche
8.2.2 Bayer AG
8.2.3 Regeneron Pharmaceuticals, Inc.
8.3 Other Companies in CNV Therapeutics Market
9 Choroidal Neovascularization Therapeutics - Licensing and Partnership Deals
10 Choroidal Neovascularization Therapeutics - Appendix
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography

1.1 List of Tables
Table 1: Choroidal Neovascularization- Classification
Table 2: Choroidal Neovascularization Therapeutics Market, Global, Revenue ($m), 2005-2010
Table 3: Choroidal Neovascularization Therapeutics Market, Global, Forecast ($m), 2010–2017
Table 4: Choroidal Neovascularization Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 5: Choroidal Neovascularization Therapeutics Market, The US, Forecast ($m), 2010–2017
Table 6: Choroidal Neovascularization Therapeutics Market, France, Revenue ($m), 2005–2010
Table 7: Choroidal Neovascularization Therapeutics Market, France, Forecast ($m), 2010–2017
Table 8: Choroidal Neovascularization Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 9: Choroidal Neovascularization Therapeutics Market, Germany, Forecast ($m), 2010–2017
Table 10: Choroidal Neovascularization Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 11: Choroidal Neovascularization Therapeutics Market, Italy, Forecast ($m), 2010–2017
Table 12: Choroidal Neovascularization Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 13: Choroidal Neovascularization Therapeutics Market, Spain, Forecast ($m), 2010–2017
Table 14: Choroidal Neovascularization Therapeutics Market, the UK, Revenue ($m), 2005–2010
Table 15: Choroidal Neovascularization Therapeutics Market, the UK, Forecast ($m), 2010–2017
Table 16: Choroidal Neovascularization Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 17: Choroidal Neovascularization Therapeutics Market, Japan, Forecast ($m), 2010–2017
Table 18: Choroidal Neovascularization Therapeutics – Phase III Pipeline, 2011
Table 19: Choroidal Neovascularization Therapeutics – Phase II Pipeline, 2011
Table 20: Choroidal Neovascularization Therapeutics – Phase I Pipeline, 2011
Table 21: Choroidal Neovascularization Therapeutics- Discovery and Pre-clinical Pipeline, 2011
Table 22: CNV Therapeutics – Most Promising Drugs Under Clinical Development, 2011
Table 23: Choroidal Neovascularization Therapeutics – Clinical Trials by Country, 2011
Table 24: Choroidal Neovascularization Therapeutics – Clinical Trials by Phase, 2011
Table 25: Choroidal Neovascularization Therapeutics – Clinical Trials by Status, 2011
Table 26: Choroidal Neovascularization Therapeutics – Prominent Sponsors, 2011
Table 27: Choroidal Neovascularization Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 28: F. Hoffman-La Roche– Ophthalmology Pipeline, 2011
Table 29: F. Hoffman-La Roche- Deals 2009-2010
Table 30: Bayer AG – CNV Pipeline, 2011
Table 31: Bayer AG Deals, 2009-2010
Table 32: Regeneron – CNV Pipeline, 2011
Table 33: Choroidal Neovascularization Therapeutics Market – Future Players, 2011
Table 34: Choroidal Neovascularization Therapeutics, Global, Deals, 2009-2011

1.2 List of Figures
Figure 1: Fluorescein Angiograms of Choroidal Neovascularization Types
Figure 2: Progression of CNV
Figure 3: When Focusing on the Center of an Amsler Grid (a), a Patient with CNV Perceives the Grid as Distorted (b)
Figure 4: Treatment Options for CNV
Figure 5: Choroidal Neovascularization Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 6: Choroidal Neovascularization Therapeutics Market, Global, Forecast ($m), 2010–2017
Figure 7: Choroidal Neovascularization Therapeutics Market, The US, Revenue ($m), 2005–2010
Figure 8: Choroidal Neovascularization Therapeutics Market, The US, Forecast ($m), 2010–2017
Figure 9: Choroidal Neovascularization Therapeutics Market, France, Revenue ($m), 2005–2010
Figure 10: Choroidal Neovascularization Therapeutics Market, France, Forecast ($m), 2010–2017
Figure 11: Choroidal Neovascularization Therapeutics Market, Germany, Revenue ($m), 2005–2010
Figure 12: Choroidal Neovascularization Therapeutics Market, Germany, Forecast ($m), 2010–2017
Figure 13: Choroidal Neovascularization Therapeutics Market, Italy, Revenue ($m), 2005–2010
Figure 14: Choroidal Neovascularization Therapeutics Market, Italy, Forecast ($m), 2010–2017
Figure 15: Choroidal Neovascularization Therapeutics Market, Spain, Revenue ($m), 2005–2010
Figure 16: Choroidal Neovascularization Therapeutics Market, Spain, Forecast ($m), 2010–2017
Figure 17: Choroidal Neovascularization Therapeutics Market, the UK, Revenue ($m), 2005–2010
Figure 18: Choroidal Neovascularization Therapeutics Market, the UK, Forecast ($m), 2010–2017
Figure 19: Choroidal Neovascularization Therapeutics Market, Japan, Revenue ($m), 2005–2010
Figure 20: Choroidal Neovascularization Therapeutics Market, Japan, Forecast ($m), 2010–2017
Figure 21: Opportunity and Unmet Need in the Choroidal Neovascularization Therapeutics Market
Figure 22: Strategic Competitor Assessment of the Major Marketed Products in CNV, 2010
Figure 23: Clinical Study Details – Lucentis
Figure 24: Clinical Study Details – Visudyne
Figure 25: Clinical Study Details – Macugen
Figure 26: Choroidal Neovascularization Therapeutics – Pipeline by Phase of Development, 2011
Figure 27: Choroidal Neovascularization Therapeutics – Technology Trends Analytics Framework, 2011
Figure 28: Choroidal Neovascularization Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 29: Choroidal Neovascularization Therapeutics – Pipeline by Mechanism of Action, 2011
Figure 30: Clinical Study Details – VEGF Trap-Eye
Figure 31: Choroidal Neovascularization Therapeutics – Clinical Trials by Country, 2011
Figure 32: Choroidal Neovascularization Therapeutics – Clinical Trials by Phase, 2011
Figure 33: Choroidal Neovascularization Therapeutics – Clinical Trials by Status, 2011
Figure 34: Choroidal Neovascularization Therapeutics – Overall Sponsors, 2011
Figure 35: Choroidal Neovascularization Therapeutics – Prominent Sponsors, 2011
Figure 36: Choroidal Neovascularization Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011
Figure 37: Choroidal Neovascularization Therapeutics Market, Drivers and Barriers, 2011
Figure 38: Implications for Future Market Competition in the Choroidal Neovascularization Market, 2011
Figure 39: Choroidal Neovascularization Therapeutics Market – Pipeline by Company, 2011
Figure 40: Market Forecasting Model

GlobalData, the industry analysis specialist, has released its new report, “Choroidal Neovascularization Therapeutics - Pipeline Assessment and Market Forecasts to 2017”. The report is an essential source of information and analysis on the global choroidal neovascularization (CNV) market. The report identifies the key trends shaping and driving the global CNV market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global CNV sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Choroidal Neovascularization Therapeutics Market is Forecast to Show high Growth until 2017

GlobalData forecasts the global Choroidal Neovascularization (CNV) therapeutics market to grow at 6.8% annually for the next seven years, to reach $4.19 billion by 2017. It was valued at $2.6 billion in 2010. This significant growth is primarily attributed to an increase in treatment rates and a high annual cost of therapy for the approved market drugs. The market has experienced tremendous growth due to the introduction of anti-VEGF (Vascular Endothelial Growth Factor) drugs for the treatment of CNV.

Choroidal Neovascularization Therapeutics Market, Global, Revenue and Forecasts ($m), 2005–2017

Source: GlobalData, Age-Related Macular Degeneration: A Guide for the Primary Care Physician, Journal of the national medical association, 2009; John Gever, Bevacizumab Tops Anti-VEGF Choice in AMD, (Age related macular degeneration), 2010

Current Treatment Options are Successful in Meeting Market Demand

GlobalData’s analysis indicates that the current competition in the CNV therapeutics market is strong and the available treatment options have been successful in meeting the market need. The current marketed products are successful in treating the underlying cause of the disease. The extent of unmet need in the CNV therapeutics market is considered to be low. The current market drugs include Lucentis (ranibizumab), approved for CNV associated with wet age related macular degeneration (AMD), Visudyne (verteporfin), approved for CNV associated with wet AMD, presumed ocular histoplasmosis and pathologic myopia, and Macugen (pegaptanib), approved for CNV associated with wet AMD. Apart from these there is Avastin (bevacizumab), which is not approved for CNV (off-label) and is in Phase III of clinical development, has gradually captured a major share of the market.

Genentech/F. Hoffmann-La Roche
Bayer AG
Regeneron Pharmaceuticals, Inc.

Order Online - visit http://www.researchandmarkets.com/reports/1821755

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.